SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is seeing heavy discussion following mixed reactions to positive topline data from its AXPAXLI Phase 3 trial for wet AMD; while the primary superiority endpoint was met, investors are debating the drug's market differentiation and durability, leading to significant price volatility and renewed buyout speculation.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. ($INFQ) is trending as it begins trading under its new ticker after a de-SPAC merger, with the community actively discussing its strong quantum technology fundamentals, low share float, and significant growth potential despite current volatile market conditions and some brokerage update delays.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is experiencing significant momentum following positive Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, which demonstrated rapid, sustained efficacy and a favorable safety profile. The community is now buzzing about the accelerated timeline for a potential commercial launch and a newly cleared FDA path for PTSD trials, seeing this as a major step towards becoming a first-to-market psychedelic medicine.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending following its definitive agreement for Hapag-Lloyd to acquire the company at $35 per share in an all-cash deal, leading to fervent community discussion. Investors are actively weighing the significant arbitrage opportunity, the potential for a massive short squeeze due to high short interest, and the likelihood of continued dividends until the deal closes, while also considering potential regulatory hurdles from the Israeli government.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to heightened community debate surrounding recent disclosures from the Epstein files, which has intensified polarized sentiment about the company's valuation and its connection to broader political narratives.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Recent news of executive departures, significant workforce cuts, and exiting international markets is driving intense conversation around GEMI. The community is sharply divided between those calling it a "scam" after massive losses and others accumulating shares, betting on a turnaround fueled by its new prediction market license and high short interest.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending after securing an $11.5 million production contract from a key U.S. defense prime and being selected as the first qualified additive manufacturing vendor for the U.S. Army's ground vehicle systems. Despite these critical advancements in aerospace and defense, the community is actively debating the stock's immediate selling pressure while many are buying dips for anticipated long-term gains.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending after its Q1 earnings report, which highlighted a new acquisition and a multi-billion dollar expansion of its partnership with Google Cloud for AI security. While some investors see a compelling "buy the dip" opportunity in the cybersecurity leader, others express concern over the cost of acquisitions and the stock's recent underperformance amid broader software sector sentiment.

eToro Group Ltd. engages in the development, management, and provision of online trading software solutions and services. The firm's trading platform, eToro, allows users to trade financial instruments. It also enables non-professionals to trade in markets that were previously the exclusive arena of professional investors. The company was founded by Johnathan Alexander Assia, Guy Gamzu, David Ring, and Ronen Assia on December 14, 2006 and is headquartered in Bnei Braq, Israel.

Etoro Group Ltd - Ordinary Shares - Class A

eToro Group Ltd

eToro is trending following its strong Q4 earnings report, which highlighted a beat on profit estimates, growth in funded accounts and assets under administration, and an expanded share repurchase program. The community is actively discussing its perceived undervaluation and solid fundamentals, often comparing it favorably against other fintech platforms.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is drawing significant attention as its FDA-approved PAPZIMEOS therapy demonstrates durable patient responses and gains early commercial traction, intensified by recent institutional investments and a competitor's regulatory setback. The community is actively debating the stock's undervaluation, anticipating strong revenue growth, and pushing past persistent price resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action...

<ul class="summary-bullets"><li>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following subcutaneous administration.</li><li>Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients.</li><li>The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.</li></ul>Alvotech (ALVO) shares were up nearly 10% in Thursday’s pre-market trade after the company announced positive top-line results from its pharmacokinetic study.The company stated that the study showed that AVT80, its biosimilar candidate to Entyvio, met all its primary endpoints.“We are very pleased with this result, which is an important milestone in the development of our proposed biosimilar to Entyvio, allowing us to proceed towards regulatory submissions,” said Alvotech COO Joseph McClellan.<h2 class="st-heading-2">Details Of The Pharmacokinetics Study</h2>Alvotech stated that it designed the study to evaluate the safety, tolerability, and immunogenicity profiles of AVT80 and Entyvio in healthy adult participants following a single 108 mg/0.68 mL subcutaneous (SC) injection.Entyvio is indicated for the treatment of moderate to severe Ulcerative Colitis and moderate to severely active Crohn’s disease in adult patients. The biologic medication’s cumulative worldwide net revenue in 2025 was about $6.4 billion, the company said.Alvotech also stated that it is currently developing AVT16, a proposed biosimilar to Entyvio for intravenous administration, while AVT80 is designed for subcutaneous administration.The Pharmacokinetic study for AVT80 is crucial to demonstrating clinical similarity between AVT16 and AVT80, the company added.<h2 class="st-heading-2">What Does Alvotech Do?</h2>Alvotech is a Reykjavik, Iceland-based biotechnology company that is focused exclusively on developing biosimilar medicines.The company has two biosimilars, Humira and Stelara, already approved and marketed in multiple markets around the world. Alvotech has partnered with multiple companies globally, including Teva Pharmaceuticals, Cipla, Dr. Reddy’s, and Lotus Pharmaceuticals, among others.&nbsp;<h2 class="st-heading-2">How Stocktwits Users Reacted</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ALVO">Alvotech</a> was in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels. The ALVO ticker was the fourth most trending ticker on the platform at the time of writing.One bullish user called the top-line results “huge news” for Alvotech.<stembedurl>https://stocktwits.com/NewsTrader_perform4nce/message/644068023</stembedurl><a href="https://stocktwits.com/symbol/ALVO">ALVO stock</a> is down 1% year-to-date and 59% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-excellent-call-with-china-xi-jinping-trip-in-april/cZbj5hCR4Z6">Trump Announces He Had An ‘Excellent’ Call With Chinese President Xi Jinping, Says He Will Travel In April To China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alvotech logo is seen displayed on a smartphone screen

Why Is ALVO Stock Rising Pre-Market Today?

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Equity

Alvotech (NASDAQ:ALVO) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have earned an average recommendation of "Hold" from the six research firms that are covering the company, MarketBeat.com reports. Two analysts have...

Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y

RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.

ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?

ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.

ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash

ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech...

Alvotech (NASDAQ:ALVO) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have received an average recommendation of "Hold" from the six analysts that are currently covering the firm, MarketBeat.com reports. Two analysts...

Alvotech (NASDAQ:ALVO) Shares Down 5.5% - Time to Sell?

Alvotech (NASDAQ:ALVO) Trading Down 5.5% - Here's Why...

Alvotech (NASDAQ:ALVO) Sees Unusually-High Trading Volume - Still a Buy?

Alvotech (NASDAQ:ALVO) Sees Large Volume Increase - Here's What Happened...

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Current Price	$4.45
Prev Close	$4.64
Open	$4.68
Dividend Yield	0.00%
50-Day Moving Average	$5.08
Beta	0.67
Avg. Volume	367,172.30
PE Ratio	20.15

52-Week High	$12.89
52-Week Low	$4.32
Market Capitalization	$1.39B
EPS (Annual)	-$0.8654
Price to Book	-7.92
Revenue Per Employee	$474,498.06

ALVO
Alvotech

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALVO News

ALVOAlvotech